Articles From: Opexa Therapeutics Announces Analyst and Investor Event to Oplink Shareholders For Change (OSC) Call on Oplink Board to Respect Shareholder Democracy and Allow New Board to Set Strategy


Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
Sign-up for Opexa Therapeutics Announces Analyst and Investor Event investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of secondary progressive multiple sclerosis (SPMS), today announced that the Company will report financial results for the three months ended June 30, 2014 after the close of trading on Thursday, August 14th.
Sign-up for Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2014 Financial Results investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of Multiple Sclerosis (MS), today reported financial results for the second quarter ended June 30, 2014 and provided an overview of the Company’s recent corporate developments.
Sign-up for Opexa Therapeutics Reports Second Quarter 2014 Financial Results and Provides Corporate Update investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit’s annual Houston area Walk MS fundraisers for the fourth consecutive year.
Sign-up for Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K.
Sign-up for Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa Therapeutics to Present at September Conferences investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® ( imilecleucel-T ), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today disclosed that the Company has commenced development in a second indication, Neuromyelitis optica (NMO). NMO is a rare autoimmune disorder, which is designated as an Orphan disease by the U.S. Food and Drug Administration (FDA). There is currently no cure and there are no FDA approved therapies for this disease.
Sign-up for Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten public offering.
Sign-up for Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014.
Sign-up for Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock investment picks
2014/10/2
By Alex MacDonald LONDON--U.K.-listed Ophir Energy PLC (OPHR.LN) said Thursday it has discovered enough natural gas at another well on Tanzania's offshore Kamba and Fulusi prospects to consider building three liquefied natural gas trains for its gas discoveries in the region.
Sign-up for Ophir Energy Says Kamba Well Finds Enough Gas For Another LNG Train investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company's Phase 2b trial comparing Fovista ® (1.5mg) combination therapy with Lucentis ® (0.5mg) versus Lucentis ® (0.5mg) monotherapy will be presented at the American Academy of Ophthalmology 2014 Annual Meeting in Chicago, Illinois.
Sign-up for Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows that Fovista® Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Sub-retinal Fibrosis in Wet AMD Patients investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This enrollment milestone payment from Novartis was triggered as a result of Ophthotech reaching the first enrollment goal under the agreement in its pivotal, multi-national Fovista ® Phase 3 clinical program and is the first of a total of $130 million in potential enrollment-based milestones under the agreement.
Sign-up for Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista® investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G.
Sign-up for Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer investment picks
Ophthotech Corporation (Nasdaq:OPHT) announced that Todd N.
Sign-up for Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the second quarter ended June 30, 2014, on Wednesday, August 6, 2014.
Sign-up for Ophthotech Corporation to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014 investment picks
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Sign-up for Ophthotech Corporation to Present at the 2014 Morgan Stanley Global Healthcare Conference investment picks
2014/8/5
Ophthotech Corporation announced today the initiation of the first of several planned expansion trials, in addition to the ongoing Fovista ® combination therapy Phase 3 clinical program.
Sign-up for Ophthotech Initiates First of Several Expansion Studies to Further Evaluate Fovista® (Anti-PDGF) Therapy in Patients with Wet Age-Related Macular Degeneration investment picks
Ophthotech Corporation (Nasdaq:OPHT) today provided an update on the Company’s business and announced financial results for the second quarter ended June 30, 2014.
Sign-up for Ophthotech Reports Second Quarter 2014 Financial Results and Provides Business Update investment picks
OPKO Health, Inc. (NYSE:OPK) , a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its second quarter ended June 30, 2014.
Sign-up for OPKO Announces Second Quarter Operating and Financial Results investment picks
OPKO Health, Inc. (NYSE: OPK) is pleased to lend its support to the legislation introduced in the United States Senate on September 16, 2014 by Senators Jeff Sessions (R-AL) and Barbara Boxer (D-CA) legislating the formation of the National Prostate Cancer Council (NPCC). The Boxer-Sessions legislation directs formation of the NPCC to develop and implement a national strategic plan to accelerate the innovation of diagnostic tools to improve prostate cancer screening and early detection, while also helping to reduce unnecessary treatment.
Sign-up for OPKO Health Supports National Prostate Cancer Council Legislation investment picks
OPKO Health, Inc. (NYSE:OPK) today announced the European launch of the 4Kscore ™ Test, the only blood test that accurately identifies risk for aggressive prostate cancer, through its wholly owned subsidiary, OPKO Health Spain.
Sign-up for OPKO Launches the 4Kscore Test in Europe investment picks
OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). This NDA is supported by data from four controlled studies covering a spectrum of patients receiving chemotherapy that commonly causes nausea and vomiting.
Sign-up for OPKO Licensee TESARO Submits New Drug Application for Rolapitant investment picks
OPKO Health, Inc. (NYSE: OPK), announced the submission of an Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA) under which Rayaldee ™ will begin clinical evaluation as an adjunctive therapy for the prevention of skeletal-related events (SREs) in patients with bone metastases undergoing anti-resorptive therapy.
Sign-up for OPKO Submits IND for Rayaldee™ as Adjunctive Cancer Therapy investment picks
OPKO Health, Inc. (NYSE: OPK ) will announce top line data from the first of two identical pivotal Phase 3 clinical trials for RAYALDEE™ and its second-quarter 2014 financial results on Monday, August 11, 2014, after the market closes.
Sign-up for OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014 Financial Results on August 11, 2014 investment picks
OPKO Health, Inc. (NYSE: OPK), announced successful top-line results from the second and final pivotal phase 3 trial of Rayaldee™. This trial is the second of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Sign-up for OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints investment picks
Commences Process to Evaluate Strategic Alternatives for Oplink Connected Business, Including Possible Sale FREMONT, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Oplink Communications, Inc. (Nasdaq:OPLK) , a leading provider of optical communication components, intelligent modules and subsystems, today announced a series of initiatives to further enhance shareholder value.
Sign-up for Oplink Announces Initiatives to Enhance Shareholder Value investment picks
FREMONT, Calif., Sept.
Sign-up for Oplink Issues Statement in Response to Engaged Capital and Voce Capital Management investment picks
FREMONT, Calif., Aug.
Sign-up for Oplink Reports Fourth Quarter and Fiscal Year 2014 Financial Results investment picks
Oplink Shareholders for Change (“OSC”), a group led by Engaged Capital, LLC (“Engaged Capital”) and Voce Capital Management LLC (“Voce Capital”), who collectively own approximately 6.2% of the outstanding shares of Oplink Communications Inc. (“Oplink” or the “Company”) (NASDAQ:OPLK), called on the board of directors of Oplink (the “Board”) to suspend its strategic decision-making process until the reconstitution of the Board at the upcoming annual meeting of shareholders (the “Annual Meeting”). In light of OSC’s nomination of two independent, highly-qualified director candidates, Jeffrey S.
Sign-up for Oplink Shareholders For Change (OSC) Call on Oplink Board to Respect Shareholder Democracy and Allow New Board to Set Strategy investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Opexa Therapeutics Announces Analyst and Investor Event to Oplink Shareholders For Change (OSC) Call on Oplink Board to Respect Shareholder Democracy and Allow New Board to Set Strategy
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices